HIV Infections Clinical Trial
Official title:
CSP #706D - HIV Seroprevalence and Risks in Veterans With Severe Mental Illness
It is suspected, but not well documented, that persons with severe mental illness (SMI) represent a significant transmission source of serious infectious diseases. SMI diagnoses are defined as schizophrenia, schizoaffective disorder, bipolar disorder, or posttraumatic stress disorder (PTSD). Severely mentally ill persons are at high risk for Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS). To assess the risk of HIV and related infections among these individuals, the National Institute of Mental Health (NIMH) Office on AIDS funded the HIV/SMI five site collaborative study "Assessing HIV/AIDS and Associated Health Risks in People with Severe Mental Illness". This Durham ERIC study supplements the NIMH HIV/SMI study with a four-year longitudinal cohort study of 300-plus SMI veterans in order to estimate the prevalence of HIV risk behaviors and HIV infection, as well as to measure utilization of health services over time. The Durham VA is the only VA site represented in the study and is collaborating with four non-VA sites including Dartmouth, University of New Hampshire, University of Connecticut and Duke University. As such, we have the additional goals of investigating health and health-care-service issues relevant to veterans with SMI and of establishing a database for the longitudinal study of veterans with SMI.
Primary Objectives: To determine the prevalence of HIV and other related infections such as
Hepatitis C, along with associated risk behaviors, in patients with severe mental illness
(SMI).
Secondary Objectives: To identify the implications for mental health and medical services
and to obtain a better understanding of the contextual factors that affect the health
problems associated with HIV risk behavior.
Primary Outcomes: The primary outcome variables are HIV seroprevalence, prevalence of HIV
risk behaviors including injection drug use and sexual promiscuity, personal and
social-contextual factors, comorbid mental disorders, and health service use among SMI
persons in each group, veterans versus non-veterans.
Intervention: N/A
Study Abstract: It is suspected, but not well documented, that persons with severe mental
illness represent a significant transmission source of serious infectious diseases. SMI
diagnoses are defined as schizophrenia, schizoaffective disorder, bipolar disorder, or
posttraumatic stress disorder (PTSD). Severely mentally ill persons are at high risk for
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS). To assess the
risk of HIV and related infections among these individuals, the National Institute of Mental
Health (NIMH) Office on AIDS funded the HIV/SMI five site collaborative study "Assessing
HIV/AIDS and Associated Health Risks in People with Severe Mental Illness". This Durham ERIC
study supplements the NIMH HIV/SMI study with a four-year longitudinal cohort study of
300-plus SMI veterans in order to estimate the prevalence of HIV risk behaviors and HIV
infection, as well as to measure utilization of health services over time. The Durham VA is
the only VA site represented in the study and is collaborating with four non-VA sites
including Dartmouth, University of New Hampshire, University of Connecticut and Duke
University. As such, we have the additional goals of investigating health and
health-care-service issues relevant to veterans with SMI and of establishing a database for
the longitudinal study of veterans with SMI.
Study participation consisted of a one-hour structured HIV-risk behavior interview and a
blood and urine sample. These samples are being tested for HIV, syphilis, hepatitis B and C,
cytomegalovirus, gonorrhea, and chlamydia at the Durham VA Microbiology Laboratory. Subject
enrollment for this study concluded 6/30/2000 with 399 total subjects enrolled. Of these 399
enrolled, 111 subjects were re-tested and re-interviewed. The percentage of subjects
enrolled at the Durham VAMC with infectious diseases is as follows: 2.6% with HIV infection;
21% with Hepatitis B core antibodies; and, 18% with Hepatitis C antibodies. Clinical
management of subjects with positive serology continues to be administered according to the
procedures developed by Richard Frothingham, M.D.
Final Results: The initial manuscript for the study was published in American Journal of
Public Health in January, 2001 and analyses for additional publications are underway. Final
Report to be submitted to Durham ERIC within 90 days of study end date (3/31/02).
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |